

REMARKS

Claims 1-11, 21 and 39-53 were pending. Claims 1-9, 11, 21, 29-50, 53-56 are cancelled. Claims 10, 51 and 52 are pending.

It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance. Reconsideration of the application in view of the above amendments and the following remarks is requested.

I. Allowable Subject Matter

Claims 10, 51 and 52 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent from including all of the limitations of the base claim. Although Applicants do not agree with the obviousness rejection, in order to expedite prosecution, claims 1-9, 11, 21, 29-50, 53-56 are cancelled, and claims 10, 51 and 52 are amended to place the claims in conditions for allowance.

II. Obviousness


Claims 1-9, 11, 21, 29-50, 53-56 are rejected as obvious. The obviousness rejection is rendered moot by the cancellation of these claims.

III. Conclusion

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: November 19, 2004


Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Best Available Copy